Peptide Muscle Growth Research Rankings: The 2024 Leaderboard

How the Scoring System Works

Every compound on this board is scored across four categories: evidence tier (human RCT earns the most points, followed by small human studies, animal studies, and in-vitro work), mechanistic clarity (does the research identify a specific pathway, receptor, or signaling cascade?), reproducibility (have independent labs replicated the findings?), and recency (studies published after 2015 score higher, reflecting improved methodology). Maximum score is 40 points. The leaderboard is a research-quality snapshot, not a performance ranking.

Scoring is intentionally conservative. A compound with one impressive rat study scores lower than a compound with three mediocre human studies, because evidence tier carries the heaviest weight in the formula. That bias toward human data is why IGF-1 separates from the rest of the field so cleanly. The gap between Rank 1 and Rank 2 is larger than the gap between any other consecutive ranks on this board.

The Starting Five: Ranks 1 Through 5

Rank 1: IGF-1 (Insulin-Like Growth Factor-1), Score 36/40. IGF-1 sits at the top of this board by a wide margin. It has decades of human clinical data, including multiple randomized controlled trials. A 1994 RCT published in the Annals of Internal Medicine (Butterfield et al., n=16) showed that recombinant IGF-1 infusion increased whole-body protein synthesis in healthy adults. Mechanistically, IGF-1 activates the PI3K/Akt/mTOR pathway, which is the most studied anabolic signaling cascade in skeletal muscle. Independent labs across the U.S., Europe, and Asia have replicated the core findings across multiple decades. The pharmaceutical drug mecasermin (Increlex) is FDA-approved specifically for IGF-1 deficiency in children, and that approval applies to mecasermin as a branded prescription product only.

Rank 2: BPC-157 (Body Protection Compound-157), Score 24/40. BPC-157 is a 15-amino-acid peptide derived from a human gastric protein. Its muscle-biology research is almost entirely preclinical. A 2018 study in the Journal of Physiology and Pharmacology (Sikiric et al.) documented accelerated tendon-to-bone healing and muscle repair in rat models. Mechanistic work points to upregulation of growth hormone receptor expression and modulation of the nitric oxide system. The reproducibility score is decent for an animal-study-dominant compound, with multiple Croatian and Taiwanese research groups publishing consistent findings. No human RCTs on muscle outcomes exist as of mid-2024, which is the primary reason it sits at Rank 2 rather than competing with IGF-1.

Rank 3: GHRP-6 (Growth Hormone Releasing Peptide-6), Score 22/40. GHRP-6 is a synthetic hexapeptide that stimulates pituitary GH release by binding the ghrelin receptor (GHSR-1a). A 1997 study in the Journal of Clinical Endocrinology and Metabolism (Bowers et al.) confirmed GH pulse amplification in healthy men, and GH's downstream effects on IGF-1 production are well-characterized. The muscle-specific data is largely indirect: researchers measure GH and IGF-1 surges rather than muscle protein synthesis directly. Animal studies show lean mass preservation in catabolic models. Mechanistic clarity is high; direct human muscle-outcome data remains thin.

Rank 4: Ipamorelin, Score 21/40. Ipamorelin is a pentapeptide GH secretagogue with a selectivity profile that researchers consider cleaner than GHRP-6, because it produces less cortisol and prolactin co-secretion in animal studies. A 1998 paper in the European Journal of Endocrinology (Raun et al.) established its GH-releasing potency in rats and pigs. Human data is limited to small pharmacokinetic studies. The muscle-biology case rests on the GH-IGF-1 axis, similar to GHRP-6, rather than direct myocyte data. It scores one point below GHRP-6 because the human evidence base is narrower.

Rank 5: CJC-1295, Score 18/40. CJC-1295 is a modified GHRH analog designed for extended half-life. A 2006 study in the Journal of Clinical Endocrinology and Metabolism (Teichman et al., n=65) showed sustained GH and IGF-1 elevation over several days in healthy adults, making it one of the few synthetic GHRH analogs with a published human dose-response study. The muscle-biology connection is indirect, running through the GH-IGF-1 axis. No studies have measured muscle cross-sectional area or protein synthesis directly in humans. The existence of human pharmacokinetic data keeps it in the top five.

Ranks 6 and 7: Promising Preclinical Profiles

Rank 6: TB-500 (Thymosin Beta-4), Score 15/40. Thymosin beta-4 is a 43-amino-acid peptide that regulates actin polymerization. Its muscle-biology research centers on satellite cell activation and tissue repair signaling. A 2010 study in the Journal of Molecular and Cellular Cardiology (Bock-Marquette et al.) showed that thymosin beta-4 promoted cardiac muscle progenitor cell migration in mouse models. Skeletal muscle data is sparser. The mechanistic story around actin dynamics and satellite cell recruitment is biologically plausible, but independent replication in skeletal-muscle-specific models is limited. It scores in the lower tier primarily because of that reproducibility gap.

Rank 7: Follistatin-Related Peptides, Score 12/40. Follistatin is an endogenous glycoprotein that inhibits myostatin, a negative regulator of muscle mass. The myostatin-inhibition pathway is one of the most studied targets in muscle-biology research. A 2009 study in Molecular Therapy (Haidet et al.) showed that follistatin gene delivery produced significant muscle mass increases in non-human primates. Peptide fragments designed to mimic follistatin's myostatin-binding domain are at an earlier research stage, with most data coming from in-vitro binding assays. The pathway scores high on mechanistic clarity; the peptide-fragment evidence scores low on evidence tier and reproducibility.

What Separates the Top Tier from the Rest?

The 14-point gap between IGF-1 and BPC-157 comes down almost entirely to evidence tier. IGF-1 has human RCT data measuring muscle-specific outcomes. Every other compound on this board either lacks human data entirely or has human data that measures a proxy endpoint (GH pulse, IGF-1 serum level) rather than muscle protein synthesis, fiber cross-sectional area, or lean mass directly. That distinction matters enormously for research quality scoring.

Mechanistic clarity is actually fairly high across the board. The GH-IGF-1-mTOR axis is well-mapped, and compounds like GHRP-6 and ipamorelin slot into it cleanly. The bottleneck for most of these peptides is the jump from animal pharmacology to human muscle outcomes. That gap is where most of the research literature currently sits, and it is the honest reason why ranks 2 through 7 cluster between 12 and 24 points rather than approaching IGF-1's score.

Recency scoring slightly penalizes IGF-1's older core studies but rewards the volume of post-2015 mechanistic work that has used IGF-1 as a reference compound. BPC-157 benefits from a steady stream of post-2015 animal studies. CJC-1295 and ipamorelin have seen less new primary research in recent years, which holds their scores flat rather than growing them.

How Should Researchers Interpret This Leaderboard?

This ranking reflects the state of published literature, not biological potency or real-world outcomes. A compound can have a compelling mechanism and still rank low because the human evidence hasn't been generated yet. Follistatin-related peptides are a clear example: the myostatin pathway is one of the most validated targets in muscle biology, but the specific peptide fragments designed to exploit it are early-stage research tools.

The leaderboard will shift as new trials are published. Several compounds in the middle tier have active or recently completed ClinicalTrials.gov registrations examining body composition endpoints. When those results publish, scores for evidence tier and reproducibility will be updated. The scoring methodology stays fixed; only the inputs change as the literature grows.

Readers using this board for educational research should cross-reference primary sources rather than treating the scores as final verdicts. Each rank entry links to representative studies, but the full literature for any compound here runs to dozens or hundreds of papers. The score is a starting point for investigation, not a conclusion.